B
Bruker
High-performance scientific instruments and high-value analytical and diagnostic solutions
About Bruker
Bruker Corporation, a name synonymous with innovation in scientific instruments, traces its roots back to 1960. The company was founded by Dr. Günther Laukien, a visionary in the field of nuclear magnetic resonance (NMR) technology. His pioneering work laid the foundation for Bruker's growth into a global leader in analytical and diagnostic solutions.
Under the leadership of Dr. Laukien, Bruker focused on developing cutting-edge technologies that would revolutionize scientific research and industrial applications. The company's commitment to innovation was evident in its early adoption and development of NMR technology, which became a cornerstone of its product offerings.
Bruker's journey was marked by significant milestones, including its initial public offering (IPO) in 2000. This event was a testament to the company's growth and its potential to expand its reach in the global market. The IPO provided Bruker with the capital needed to invest in research and development, further solidifying its position as a leader in the industry.
Throughout its history, Bruker has been at the forefront of technological advancements, continuously expanding its product portfolio to include a wide range of analytical tools. These tools have been instrumental in advancing research in fields such as life sciences, materials science, and environmental analysis.
Today, Bruker Corporation stands as a testament to the power of innovation and the impact of scientific discovery. Its legacy is built on a foundation of excellence, driven by a commitment to providing researchers and industries with the tools they need to push the boundaries of what is possible.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1960
- Headquarters
- Billerica, United States
- Listing
- IPO 2000
- Employees
- 4,879
- Open positions
- 147
- Dealroom signal
- 44.8/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Biotechnology, Neurology, Agritech, Microbiology
- Technology
- Hardware, Big Data, Deep Tech, Nanotech, Computer Vision
- Business model
- Manufacturing, SaaS
- Client focus
- b2b
- Investment activity
- 59 companies, latest Aug 2026
- Capital deployed
- $615M
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO CONVERTIBLE✓Other financing | Sep 2025 | $600M | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | May 2024 | $0 | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Bruker is 270K monthly website visits, down 6.9% over the last three months. Bruker's team grew 42% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Atinary TechnologiesEpalinges, SwitzerlandMachine learning (ML) to accelerate the materials discovery process
$20Mvaluation
MimetasOegstgeest, NetherlandsDeveloping physiologically relevant 3D human disease models and partnering with global pharmaceutical companies to create therapies for untreatable diseases
$82Mvaluation
NoscendoDuisburg, GermanyOffers a completely new way of identifying pathogens - through a paradigm shift based on proprietary algorithms and software harnessing next-generation sequencing
$22Mvaluation
TofwerkBern, SwitzerlandTime-of-flight mass spectrometers for research that demands exceptional speed and sensitivity
→
Mercy BioAnalyticsNatick, United StatesMercy BioAnalytics Home - Mercy BioAnalytics
$236Mvaluation
Biocrates Life SciencesInnsbruck, AustriaBiocrates Life Sciences AG, developer of targeted metabolic phenotyping solutions, supports the discovery and validation of biomarkers for complex diseases
$3.9Mvaluation
OlarisFramingham, United StatesBiomarkers Of Response (BoR) | Olaris
→
Recipe Chemicals + InstrumentsMunich, GermanyRECIPE Chemicals + Instruments GmbH ⎜ Solutions for Clinical Diagnostics
→
RI
RidomMünster, Germany
→
Terrain BiosciencesUnited StatesAI-driven mRNA design and manufacturing for rapid RNA therapeutics development
$36Mvaluation
Akribion TherapeuticsZwingenberg, GermanyAkribion Genomics discovers and develops groundbreaking CRISPR nucleases into a new class of genetics-based cancer therapies and advanced genome editing tools
$35Mvaluation
BT
brainQr TherapeuticsGöttingen, Germany
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Thomas Weisel Partners
Other known investors3 additional known investors
BioCube
EPFL Innovation Park
Luminate Accelerator
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bruker on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bruker’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.